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Effects of acetate and bicarbonate dialysate in stable chronic dialysis
patients. The effects of acetate and bicarbonate dialysate on the
biochemical and clinical parameters of 16 stable chronic hemodialysis
patients were investigated in a double-blind crossover study. A central
delivery system was used for both types of dialysates with identical
sodium concentrations (138 mEqtliter) and osmolality in a single-pass
dialysate flow. The results indicate that dialysis with bicarbonate leads
to significantly less hypoxemia (P 0.001) and hypotensive episodes (P
 0.002) than with acetate. Pre- to post-dialysis blood pressure changes
were also more marked during acetate dialysis. Older patients with
recurrent hypotension on acetate benefit most from bicarbonate dialy-
sate. This group of patients appears to metabolize acetate more slowly
and has a significantly lower post-dialysis bicarbonate concentration (P
0.005) than asymptomatic patients during dialysis with acetate
dialysate.
Effet d'un dialysat avec acetate ou bicarbonate chez des hémodialyses
chroniques stables. Les effets d'un dialysat avec acetate ou bicarbonate
sur les paramètres biochimiques et cliniques de 16 hémodialyses stables
ont été explores par une étude croisée en double insu. Un système
d'apport central a etC utilisé pour les deux types de dialysats, avec des
concentrations de sodium (138 mEq/liter) et une osmolalitC identiques
avec un flux de dialysat non recycle. Les résultats indiquent que la
dialyse avec du bicarbonate entraIne une hypoxCmie (P < 0,001) et des
episodes d'hypotension (P < 0,002) significativement moindres qu'avec
l'acétate. Les modifications de pressions sanguines pré- et
post-dialytiques Ctaient egalement plus marquees au cours de Ia dialyse
en acetate. Les patients les plus hgés qui avaient plus d'hypotension en
acetate ont le plus bénéficié de Ia dialyse en bicarbonate. Ce groupe
semble mCtaboliser l'acCtate plus lentement et a une concentration de
bicarbonate post-dialytique significativement plus faible (P < 0,005) que
les malades asymptomatiques qui utiisent un dialysat avec de l'acCtate.
Several studies have shown the beneficial effects of bicarbon-
ate dialysate in reducing the morbidity associated with dialysis
in critically ill patients [1—41. These benefits include a lower
incidence of arterial hypotension [1, 3, 4], improved left
ventricular stroke work and stroke volume [2], and lower
incidence of nausea, vomiting, and headache [1]. However, the
advantages of using bicarbonate dialysate in stable outpatient
chronic dialysis patients has been the subject of debate [5—111.
While some studies have shown a significant improvement in
dialysis-associated morbidity [5—9], others have not been able
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to demonstrate similar improvements [10, 11]. Two confound-
ing variables have been suggested as the cause for these
discrepant results [10, 12—14]. The first is that the osmolality of
the two types of dialysate used in some studies has been
different, primarily due to differences in the sodium concentra-
tion. The second is that some studies have used large surface
area dialyzers, allowing an influx of acetate that may have
exceeded the patient's ability to metabolize it efficiently to
bicarbonate [12—16]. In addition, technical difficulties in the
ability to prepare bicarbonate dialysate for a central delivery
system have hampered the study of inter- and intradialytic
subjective symptoms in a double-blind fashion or in a large
outpatient dialysis population. Bicarbonate dialysis has, there-
fore, been restricted to use in individual bicarbonate delivery
systems, resulting in markedly higher per-treatment costs.
The recent introduction of a new bicarbonate dialysate prep-
aration that can be used in central delivery systems has allowed
us to investigate the differences in intra- and interdialytic
morbidity in a large outpatient dialysis facility in a double-blind
crossover study using "high" dialysate sodium concentration.
The results of our study indicate that bicarbonate dialysate can
be prepared easily for central delivery, and that its use im-
proves intradialytic symptoms and interdialytic well-being in
this outpatient population, particularly in a subset of patients
with recurrent intradialytic hypotension.
Methods
Sixteen patients constituting an entire dialysis shift at the
West Surburban Artifical Kidney Center (Framingham, Massa-
chusetts, USA) were asked to participate in the study and
informed consent was obtained. All were chronic stable outpa-
tient dialysis patients and were free of recent hospitalizations
and any evidence for recent or current symptoms of fluid
overload or cardio-respiratory diseases. The characteristics of
these patients are listed in Table 1. Six of the 16 patients
(indicated with an asterisk in Table 1) experienced recurrent
symptomatic hypotension during many of their previous dialy-
ses. These six patients were older (mean age 69.8 7.8 yrs;
range 55 to 77 yrs) than non-symptomatic patients (mean age
59.9 12.9 yrs; range 41 to 81 years), but were otherwise not
different in the etiology of renal disease or associated medical
condition such as diabetes or heart disease.
The study period duration was 3 months. During the first
month, patients were dialyzed with acetate dialysate; this was
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Table 1. Clinical characteristics of patients
Patient Age Sex
Treatment
time, hours
Time on
dialysis, months Renal diagnosis Associated diagnosis
*DA 77 F 4.0 14 GN Diabetes
SB 61 M 4.5 26 GN Angina
MB 59 F 4.0 29 Nephrosclerosis —
*CB 70 F 4.0 8 Nephrosclerosis —
GC 81 M 5.0 > 100 Pylo —
DC 61 F 4.0 79 PCKD —
LC 40 F 5.0 40 SLE —
*MH 73 F 4.0 27 Papillary necrosis Pacemaker
LH 73 M 4.0 > 100 GN Peripheral vascular disease
LK 41 F 4.5 32 Nephrosclerosis —
*AL 55 M 4.0 23 Nephrosclerosis —
*JM 75 M 4.5 18 Nephrosclerosis —
CR 66 M 4.0 46 GN Angina
HS 65 F 4.5 > 100 PCKD —
GS 52 F 4.0 54 GN —
*AT 69 M 4.0 8 Interstitial nephritis —
Abbreviations are: ', symtomatic patients; GN, presumed glomerulonephntis; Pylo, chronic pylonephritis; PCKD, polycystic kidney disease;
SLE, systemic lupus erythematosis.
Acetate Bicarbonate
Na, mEqiliter 138 138
Cl, mEqlliter 104 105
K, mEqiliter 2.0 2,0
Ca, mEqiliter 3.5 3.5
Mg, mEqiliter 1.5 1.5
Acetate, mEqiliter 41 4.0
HCO3, mEqiliter — 36
Dextrose, mg/dl 100 100
followed by a month on bicarbonate dialysate. Subsequently,
all patients were returned back to acetate dialysis for a third
month. The composition of the dialysate in each phase of the
study is shown in Table 2. The nominal and the measured
sodium concentration and osmolalities of both dialysates were
identical (Technicon autoanalyzer, Massachusetts, USA).
A bicarbonate central delivery system (Centralyte, Erika
Inc., Rockleigh, New Jersey) was used in the study. The
dialysate was supplied in two components, an acid concentrate
containing calcium chloride, magnesium chloride, acetic acid,
and water and a powder (dry pack) containing sodium chloride,
sodium bicarbonate, potassium chloride, and dextrose. The
concentration of these components is such that when mixed
with reverse osmosis water, the final concentration is as shown
in Table 2. Separate conductivity as well as pH meters were
used to monitor the appropriate concentration of the dialysate
prior to delivery to the patient's station. To ensure the double-
blind nature of the study, both types of dialysate were prepared
in a separate room at times other than those during which
patients and staff participating in the study were present. The
central delivery storage area was also in a separate room and
generally not accessible to the staff. Several trial phases of the
study were conducted before initiation of the data collection
phase, and the exact date of initiation of each phase of the study
and the type of dialysate used was not communicated to the
patients or staff. Dialysate flow was single-pass, at a flow rate of
500 ml/min. The dialyzers used were cuprophane hollow fiber
dialyzers, with a surface area of 0.8m2 (HPF-100, Erika, Inc.).
There were no changes in the patients' dialysis prescription, nor
were any dietary modifications made during the study. Average
dialysis time was 4.25 hrs. Blood flow was 300 mI/mm.
Transmembrane pressure (TMP) was calculated to achieve each
patient's estimated dry weight. Patients participating in the
study had no effective residual renal function.
Subjective and objective evaluation included:
a) Blood gases drawn weekly from each patient participating
in the study at the beginning of dialysis, 1 hr after initiation and
immediately post dialysis on room air. Bloods were drawn
aneorobically in heparinized syringes, capped, and iced imme-
diately, and analyzed within 2 hrs for pH, P°2 and pCO2; serum
bicarbonate concentration was calculated according to the
Henderson-Hasselback relationship.
b) A chemistry profile, including 20 standard chemical deter-
minations (SMA-20), was obtained on each patient weekly at
the beginning of each dialysis of the week (Monday or
Tuesday).
c) The time-averaged concentration of urea (TACUrea) was
calculated once in each patient at the mid-period of each phase
of the study by determining pre- and post-dialysis blood urea
nitrogen (BUN) concentrations, C1 and C2, respectively, and
the BUN prior to the following dialysis (C3). TAC was calcu-
lated according to the formula [17]:
TAC _ (C1 + C2)TD + (C2 + C3)ID
2 (TD + ID)
Where T = dialysis time
= interdialytic time.
d) Holter monitor. Five patients were also asked to partici-
pate in a study on the effects of different dialysate on the
frequency of cardiac arrhythmias. A single 24-hr Hotter monitor
was done on each of these patients during each phase of the
study.
e) Frequency of hypotension. The frequency of hypotension,
defined prospectively as diastolic blood pressure 20 mm Hg
below the pre-dialysis blood pressure, was recorded by the
nursing staff. Therapy for symptomatic hypotension included
Table 2. Dialysate composition
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Table 3. Blood gases
Acetate Bicarbonate Acetate P12 P,,..3
Pre pH 7.38 0.005 7.37 0.005
Pre P0,,, mm Hg 93.2 0.96 95.5 1.08
Pre PCO,,, mm Hg 35.2 0.38 35.7 0.47
Pre HCO3, mM/liter 20.2 0.27 19.8 0.29
P02 at 1 hr 77.3 1.36 88.6 1.22
P02 at hr/Pre P02 0.83 0.01 0.93 0.01
Post P02 81.7 1.40 88.4 1.12
Post P02/Pre P02 0.87 0.02 0.93 0.01
Post HCO,,, mM/liter 21.8 0.3 24.2 0.3
Post PCO,,, mm Hg 30.9 0.57 34.4 0.54
Post pH 7.46 0.006 7.46 0.005
Post HCO,/Pre HCO,, 1.10 0.019 1.24 0.21
7.36 0.006
92.1 1,60
35.9 0.5
20.2 0.4
78.3 1.57
0.85 0.02
83.0 1.48
0.90 0.02
21.8 0.3
32.8 0.58
7.43 0.007
1.11 0.027
NS
NS
NS
NS
0.001
0.001
0.001
0.01
0.001
0.001
NS
0.001
NS
NS
NS
NS
0.001
0.001
0.004
NS
0.001
0.004
0.008
0.001
P1_2: P value for difference between first acetate dialysate phase and bicarbonate.
P23: P value for difference between bicarbonate dialysate and second acetate phase.
Table 4. Pre-dialysis biochemical data
Acetate Bicarbonate Acetate P,, P,,..3
K, mEq/liter 5.2 0.08 5.2 0.09
TG, mg/dl 265 21.7 265 24.3
Cholesterol, mg/dl 202 6.9 202 8.5
Calcium, mg/dl 9.2 0.10 9.7 0.11
Phosphate, mg/dl 4.6 0.16 4.8 0.14
5.5 0.11
301 27.8
200 7.8
9.7 0.12
4.5 0.17
NS
NS
NS
0.0001
NS
NS
NS
NS
NS
NS
Mean SEM
Abbreviations same as Table 3.
placement of the patient in the Trendelenberg position and
infusion of 0.9% saline, as determined by the nursing staff
according to each patient's symptoms and blood pressure
response. The volume of saline administered during each dial-
ysis for symptomatic hypotension was recorded. Manitol or
hypertonic saline were not used in the treatment of hypoten-
sion. Pre- and post-dialysis sitting blood pressures were also
recorded in each patient.
f) Subjective assessment. Patients were asked to note the
incidence of symptoms of nausea, vomiting, fatigue, and
cramps during each dialysis.
Results are presented as mean SEM. Statistical analysis
between different dialysis phases was determined by Student's
test and by analysis of variance.
Results
The mean of the pre-dialysis blood gases is shown in Table 3.
There was no statistically significant difference in pre-dialysis
pH, P°2, pCO2, and calculated bicarbonate between different
phases of the study. However, blood gases drawn 1 hr after
initiation of dialysis showed a significant difference in the P°2
between the acetate and bicarbonate dialysate phase. Thus,
during the acetate phase, patients showed a significant decrease
in P°2, with mean P°2 at 1 hr approximately 0.83 0.01 of the
pre-dialysis P02 (P 0.001). However, during the bicarbonate
phase, the extent of hypoxemia was significantly less, with the
ratio of p02 at 1 hr to pre-dialysis P°2 = 0.93 0.01 (P 0.001
from the acetate phase). When patients were placed back on the
acetate phase, the hypoxemia at 1 hr became evident again. The
hypoxemia associated with acetate dialysate persisted through-
out dialysis, with the P°2 at the end of dialysis still showing a
significant decrease from pre-dialysis values (PO2 post/pO,, pre
= 0.87 0.02 for the first acetate phase and 0.90 0.02 for the
second acetate phase), whereas during bicarbonate dialysate,
the P°2 remained stable throughout dialysis and was only
slightly less than pre-dialysis values.
Post-dialysis pCO2 and bicarbonate levels were also signifi-
cantly different between the different dialysate phases. Thus,
post-dialysis pCO2 was lower during both acetate phases (P
0.05 from pre-dialysis) and stable during the bicarbonate dialy-
sis. At the end of dialysis, the serum bicarbonate was in the
physiologic range (22 to 30 mEq/liter) and significantly higher
than pre-dialysis during the bicarbonate phase. During the
acetate phases, the serum bicarbonate level immediately post-
dialysis was still below the normal range of bicarbonate con-
centration. The pH however was not markedly different be-
tween any of the phases pre or post dialysis.
Biochemical profile drawn pre-dialysis weekly showed no
notable differences between different dialysate phases, with the
exception of calcium which was significantly higher during the
bicarbonate dialysate phase than during the first acetate phase
(Table 4).
The number of prospectively defined intradialytic hypoten-
sive episodes experienced by patients was, however, markedly
different between acetate and bicarbonate dialysate, with all
treatment parameters remaining constant (Table 5). Thus, the
number of hypotensive episodes during the initial acetate dial-
ysate phase was 111, whereas the incidence decreased to 24
during the bicarbonate phase (P ' 0.0002). On the subsequent
acetate phase, the number of hypotensive episodes increased to
51 episodes. When the frequency of hypotensive episodes was
analyzed, the six symptomatic patients were found to account
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Table 5. Number of hypotensive episodes/month
Patient Acetate Bicarbonate Acetate
*1 10 7 9
2 2 1 0
3 1 2 0
*4 9 0 8
5 4 1 0
6 5 0 6
7 8 2 0
*8 12 2 5
9 9 0 1
10 2 4 0
*11 12 0 7
*12 9 1 4
13 7 0 6
14 2 2 1
15 — 1 0
*16 19 2 4
Total 111 25 51
Symptomatic patients only: 71(64%) 12 (48%) 37 (72%)
Symbol: * symptomatic patients.
for the majority of the hypotensive episodes during both acetate
phases. Thus, these six patients (37% of the population) ac-
counted for 71 episodes or 64% of the hypotensive episodes
during the initial acetate phase. These symptomatic patients
appear to have experienced significantly more improvement
with bicarbonate dialysate than the other ten patients. Thus,
their incidence of hypotensive episodes decreased from 71
during the first acetate phase to 12 episodes (48%) during the
bicarbonate phase.
The amount of saline used to treat hypotension mirrored the
number of hypotensive episodes. Approximately 15 liters of
saline was used to counteract hypotension during the acetate
dialysate phase, but only 5 liters during the bicarbonate phase
and 10 liters during the subsequent acetate phase (Table 6). The
six patients with more frequent hypotension received the ma-
jority of the saline during the acetate dialysate phase (12 out of
a total of 15 liters), but received only 1.7 liter (35%) during the
bicarbonate phase, proportional to their number in the study.
In line with the decrease in hypotensive episodes,
intradialytic (pre- to post-dialysis) BP changes were higher
during dialysis with acetate than with bicarbonate, particularly
for the symptomatic patients. During the acetate phase, the
mean decrease in systolic pressure for all patients was 22.0
1.6 mm Hg and 4.6 0.7 mm Hg in diastolic BP, whereas
during the bicarbonate phase, the intradialytic change in BP
was less: 15.6 1.5 mm Hg for systolic BP and 3.4 0.8 mm
Hg for diastolic BP. This was statistically significant for the
systolic BP only (P  0.003). However, when considering the
symptomatic patients, the difference in intradialytic BP changes
were more marked: during the acetate phase, the average
decrease in intradialytic systolic BP was 24.6 2.3 mm Hg but
only 14.3 2.3 mm Hg during the bicarbonate phase (P 0.02);
similarly, diastolic BP decreased by 6.6 1.3 mm Hg during the
acetate phase and by only 2.6 1.1 mm Hg during the
bicarbonate phase (P  0.017).
The mean time-averaged urea concentration (TAC urea)
determined for all patients during each phase of the study is also
shown in Table 7. It is seen that during the bicarbonate phase,
Table 6. Volume of 0.9% saline administered for hypotensive
episodes/month
Patient Acetate Bicarbonate Acetate
*1 1,950 1,000 1,150
2 200 200 -4—
3 350 350 —0—
*4 1,600 —0— 1,500
5 200 —0— 450
6 —0-- —0-- 1,400
7 500 250 —0—
*8 2,500 750 2,500
9 750 —0-- 400
10 —0-- 650 —0--
*11 1,200 —0— —0—
*12 2,300 400 650
13 750 —0— 600
14 200 600 300
15 —0— 200 —0—
*16 2,450 450 700
Total: 14,950 4,850 9,650
Symptomatic patients only: 12,000 (80%) 1,700 (35%) 6,500 (67%)
Symbol: * symptomatic patients.
Table 7. TAC,- (mg/dO, mean of 16 patients
Acetate Bicarbonate Acetate P,2 P2_3
56.7 3.2 60.9 3.1 55.0 2.8 0.05 0.03
Abbreviations same as Table 3.
Table 8. Selected symptoms, total number of episodes
during each phase
Acetate Bicarbonate Acetate P1_2 P3
Nausea 31 (l7)* 23 (9) 28 (15) NS NS
Vomiting 11 (8) 6 (2) 10 (9) NS NS (0.02)
Cramping 32 (22) 36 (12) 13 (5) NS 0.001
Abbreviations same as Table 3.
Numbers in parentheses indicate the incidence of these episodes in
symptomatic patients only.
TAC urea increased from 56.7 3.1 mg/dl to 60.9 3.1 mg/dl(P  0.05) and decreased again with return to the acetate phase
to 55.0 2.8 mg/dl (P  0.03).
Results of the symptoms questionnaire, shown in Table 8,
showed a decrease in the number of adverse symptoms during
the bicarbonate phase, particularly for the symptomatic pa-
tients. However, these changes, for the most part, were not
statistically significant.
Holter monitoring showed too large an inter and intra-
recording fluctuation for each patient, even though they were
the average of 3 separate 24-hr recordings during each month of
the study (data not shown). These large fluctuations persisted
even when the recording was analyzed for only 8 hrs that
spanned the dialysis procedures.
Discussion
The results of this prospective, double-blind crossover study
indicate that, in chronic stable dialysis patients, bicarbonate
Acetate and bicarbonate dialysate in stable patients 539
dialysate decreases the extent of dialysis-associated hypoxemia
and improves the ability of dialysis to correct their acidosis by
the end of dialysis. Bicarbonate dialysate also decreases the
incidence of hypotension and the volume of saline used to treat
symptomatic hypotension, particularly in some patients who
are prone to acetate dialysis-associated hypotensive episodes.
By implication, the number of nursing staff intervention for
treatment of hypotension also decreased during the bicarbonate
phase.
The increase in the incidence of hypotension noted in the
study, as well as others when acetate is used, is probably
multifactorial. Although the effect of acetate on cardiac con-
tractility is controversial [2, 11, 181, most studies agree on the
vasodilatory effect of acetate [19—21]. In addition, the hypoxe-
mia associated with acetate dialysis may play a significant
factor in the pathogenesis of hypotension [22—24].
Recently, other studies with similar designs did not show
such a difference in hypoxemia between acetate and bicarbon-
ate [2, 10, 33]. However, it is important to note that the
dialysate delivery system in these studies consisted of a
recirculating system [10], which attenuates loss of CO2 and
bicarbonate from the blood and the rate of infusion of acetate
from the dialysate during the acetate phase, or employed
different base and sodium concentrations [2, 33]. Single-pass
dialysate delivery, as performed in this study, is the most
common method of dialysate delivery.
The sensitivity of some patients to the hemodynamic effects
of acetate is likely to be due to their different rates of metabo-
lism of acetate to bicarbonate [3, 26—31] or to their sensitivity to
the presence of acetate [32]. It is interesting that the six patients
who seemed to have the greater incidence of hypotension were
older and had significantly lower mean serum bicarbonate levels
at the end of dialysis when dialyzed with acetate dialysate than
the other ten patients (20.0 0.77 vs. 22.9 0.51, P 0.005),
suggesting a lower rate of conversion of acetate to bicarbonate
in these patients. During bicarbonate dialysis, there was no
difference in the post-dialysis serum bicarbonate levels between
these subsets of patients. It is possible, therefore, that measure-
ments of serum bicarbonate at the end of dialysis with acetate
may indicate patients who have slow acetate metabolism and
are likely to be acetate intolerant.
The increase in TACurea when there were no changes in
dialytic clearance or other dialytic parameter (dialysis time,
blood and dialysate flow, dialyzer type or surface area) suggests
an improvement in dietary intake and represents an increase in
daily protein intake of approximately 10% (0.1 glkglday) [17].
This is a modest increase, in line with the small increase in
pre-dialysis weight and the decrease in the incidence of nausea
and vomiting experienced by patients during the bicarbonate
phase of the study.
The discrepancy between the results of the first acetate phase
and the last acetate phase is also interesting. The frequency of
hypotension and the volume of saline required during the
second acetate phase was less than during the initial acetate
phase. Analysis of the data of the second acetate phase also
indicated that the majority of these symptoms occurred toward
the second half of the month, suggesting a carryover effect of
the bicarbonate phase. Recent studies have indicated that
hemodialysis patients achieve a stable pre-dialysis bicarbonate
concentration after 3 months of dialysis with bicarbonate dial-
ysate, suggesting that there is a "bicarbonate buffer store" that
needs to be repleted [7, 33].
In summary, the present study has documented a significant
improvement in the inter- and intradialytic symptoms of pa-
tients using bicarbonate dialystate. This improvement is partic-
ularly marked in a subset of patients who may have a slower
rate of metabolism of acetate. The availability of techniques for
central delivery of bicarbonate should encourage its use in large
outpatient dialysis facilities, since it has no significant side
effects, is more sound physiologically [34, 35], and may signif-
icantly reduce the economic disadvantages of bicarbonate dial-
ysate.
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